Curevo
Seattle, Washington, United States · Biotechnology, Healthcare, Mobile
Curevo is a clinical-stage biotechnology company dedicated to developing vaccines with improved tolerability and accessibility. Its lead product is amezosvatein, a non-mRNA adjuvanted sub-unit vaccine to prevent shingles, a serious medical condition involving a painful, blistering skin rash where 10-18% of people also develop serious, long-lasting nerve pain.
Key facts
- Headquarters
- Seattle, Washington, United States
- Employees
- 44
- Industries
- Biotechnology, Healthcare, Mobile
- Website
- curevovaccine.com
- Company page
Recent activity at Curevo
- : Curevo
- : Curevo Vaccine has closed a $110 million Series B funding round, led by Medicxi, to further develop its shingles vaccine, amezosvatein. The investment will support the expansion of their Phase 2 program to include more participants over age 70.
- : Curevo Raises $110 Million with Support from Medicxi and Other Investors to Advance Amezosvatein Shingles Vaccine
- : Curevo Vaccine Announces Oral Presentation of Positive Outcomes for Amezosvatein at World Vaccine Congress
- : Curevo, Inc
- : Curevo Vaccine Announces $26 Million Series A1 Financing To Support Clinical Development Of Next-Generation Subunit Vaccines
- : Curevo Vaccine Announces $60 Million Series A Financing To Support Clinical Development Of Next Generation Subunit Vaccines
Curevo funding history
| Date | Round | Amount |
|---|---|---|
| Mar 2025 | Venture | $42.4M |
| Mar 2025 | Series B | $110.0M |
| Nov 2022 | Venture | $22.0M |
| Nov 2022 | Series A | $26.0M |
| Feb 2022 | Series A | $60.0M |
Leadership
- George Simeon, CEO
- Charles Petty, Director
- Baeksik Bae, Director
- Jae Uk Jeong, Director
- Mario Barro, Director
- George Simeon, Executive Officer, Director
- Emma Fritzen, Director, Program Management
- Haijing Qin, Clinical Trials and Medical Research
- George Simeon, Strategic Alliances, Global Commercialisation
- Guy De La Rosa, Chief Medical Officer
Verified email and direct lines for Curevo’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Curevo in the news
- Curevo Vaccine Reports Efficacious Phase 2 Results for Amezosvatein in Shingles Prevention - Contagion Live (Oct 31, 2024)
- Curevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine - GlobeNewswire (Mar 17, 2025)
- Curevo Vaccine Announces $26 Million Series A1 Financing to Support Clinical Development of Next-Generation Subunit Vaccines - Business Wire (Nov 16, 2022)
- Curevo to be Acquired by Lilly to Advance Next-Generation Shingles Prevention - GlobeNewswire (May 26, 2026)
- Curevo Vaccine Announces $60 Million Series A Financing to Support Clinical Development of Next Generation Subunit Vaccines - Business Wire (Feb 10, 2022)
Companies similar to Curevo
- DYRT, INC. · Mobile, Platforms, Sports
- TryMyUI · Mobile, Platforms, Sports
- Valera Health · Healthcare, Mobile, Sports
- PrizePicks · Mobile, Platforms, Sports
- Pyxis Oncology, Inc. · Biotechnology, Healthcare
About Curevo: questions and answers
What does Curevo do?
Curevo is a clinical-stage biotechnology company dedicated to developing vaccines with improved tolerability and accessibility. Its lead product is amezosvatein, a non-mRNA adjuvanted sub-unit vaccine to prevent shingles, a serious medical condition involving a painful, blistering skin rash where 10-18% of people also develop serious, long-lasting nerve pain.
Where is Curevo headquartered?
Curevo is headquartered in Seattle, Washington, United States.
How many employees does Curevo have?
Curevo has about 44 employees.
Has Curevo raised funding?
Yes. Fundz has recorded 5 funding events for Curevo. The most recent, $42.4M, was in Mar 2025.
Who leads Curevo?
George Simeon is a CEO at Curevo.
What is the latest news on Curevo?
On Mar 18, 2025, Curevo
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy